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 20 
Abstract 21 
Natural hosts of simian immunodeficiency virus (SIV), such as African green monkeys (AGMs), 22 
do not progress to AIDS. This associates with an absence of a chronic type I interferon (IFN-I) 23 
signature. It is unclear how the IFN-I response is downmodulated in AGMs. We longitudinally 24 
assessed the capacity of AGM blood cells to produce IFN-I in response to SIV and Herpes 25 
Simplex virus (HSV). Phenotype and function of plasmacytoid dendritic cells (pDCs) and other 26 
mononuclear blood cells were assessed by flow cytometry and expression of viral sensors 27 
measured by RT-PCR. pDC displayed low BDCA-2, CD40 and HLA-DR expression during acute 28 
SIVagm infection. BDCA-2 was required for sensing SIV, but not HSV, by pDCs. In acute infection, 29 
AGM PBMCs produced less IFN-I upon SIV stimulation. In chronic phase the production was 30 
normal, confirming that the lack of chronic inflammation is not due to a sensing defect of pDCs. 31 
In contrast to stimulation by SIV, more IFN-I was produced upon HSV stimulation of PBMC 32 
isolated during acute infection, while the frequency of AGM pDCs producing IFN-I upon in vitro 33 
stimulation with HSV was diminished. Indeed, other cells started producing IFN-I. This increased 34 
viral sensing by non-pDCs was associated with an upregulation of TLR3 and IFI16 caused by IFN-I 35 
in acute SIVagm infection. Our results suggest that, as in pathogenic SIVmac infection, SIVagm 36 
infection mobilizes bone marrow precursor pDC. Moreover, we show that SIV infection modifies 37 
the capacity of viral sensing in cells other than pDCs which could drive IFN-I production in 38 
specific settings.  39 
  40 
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 41 
Importance 42 
The effect of HIV/SIV infections on the capacity of plasmacytoid dendritic cells (pDC) to produce 43 
IFN-I in vivo is still incompletely defined. As IFN-I can restrict viral replication, contribute to 44 
inflammation and influence immune responses, alteration of this capacity could impact viral 45 
reservoir size. We observed that even in non-pathogenic SIV infection, the frequency of pDC 46 
capable to efficiently sense SIV and produce IFN-I is reduced during acute infection. We 47 
discovered that, concomitantly, cells other than pDCs increased their ability of viral sensing. Our 48 
results suggest that pDC-produced IFN-I upregulate viral sensors in bystander cells, the latter 49 
gaining the capacity to produce IFN-I. These results indicate that in certain settings, cells other 50 
than pDCs can drive IFN-I-associated inflammation in SIV infection. This has important 51 
implications for the understanding of persistent inflammation and the development of anti-52 
inflammatory treatment strategies in HIV infection. 53 
Introduction 54 
Type I Interferons (IFN-I) play an important role in Human immunodeficiency virus (HIV) and 55 
simian immunodeficiency virus (SIV) infection in humans and macaques (MACs). IFN-I can limit 56 
viral replication through several mechanisms: upregulation of restriction factors (23), 57 
maturation of antigen-presenting cells (13), activation of NK cells (42) and induction of 58 
apoptosis in infected cells (22). Indeed, exogenous administration of IFNα in chronically infected 59 
HIV patients decreased viremia by seventy-five percent (2). Similarly, IFNα administration in the 60 
chronic phase of SIVagm or SIVsmm infection reduced viral loads (20, 50). In one study, it could 61 
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suppress viral rebound in HIV patients upon antiretroviral treatment interruption (3). Finally, 62 
IFN-I blockage in acute SIVmac infection increased the viral reservoir and accelerated 63 
progression to AIDS (45). However, IFN-I production can also be detrimental: IFN-I can 64 
contribute to chronic immune activation (IA) (18), induce apoptosis of uninfected bystander 65 
cells (17) and drive cells to a short-lived effector cell differentiation program (46). Interferon-66 
stimulated gene (ISG) expression associates with disease progression in HIV infection (30, 35, 67 
43, 46). Evidence for the detrimental role of chronic IFN-I responses has come from the natural 68 
hosts of SIV, such as African green monkeys (AGMs) and sooty mangabeys (SMs) (47). These 69 
natural hosts have asymptomatic SIV infections, despite viremia similar to those found in 70 
HIV/SIVmac infections. Non-pathogenic SIV infection in natural hosts associates with a lack of 71 
chronic inflammation (29). This is despite a robust inflammatory response, exemplified by an 72 
increase in ISG expression and production of cytokines, such as IL-15, during acute infection (6, 73 
19, 20). However, this inflammatory response is downmodulated by the end of acute infection. 74 
Peak IFN-I levels have been found to be lower in the plasma and lymph node cells of SIV-75 
infected AGMs than in MACs, indicating differences in IFN-I production between the two species 76 
in vivo (9, 19). Nonetheless, exogenous injection of IFN-I at the peak of IFN-I production did not 77 
alter the ISG profile observed in AGMs (20). Moreover, AGM and SM plasmacytoid dendritic 78 
cells (pDCs) produce high IFN-I levels upon in vitro stimulation with synthetic TLR7/9 ligands, SIV 79 
or Herpes simplex virus 1 (HSV) (5, 9, 11).  80 
PDCs are responsible for the majority of IFN-I production in blood upon in vitro stimulation with 81 
HIV and HSV (12, 49). In chronically infected HIV patients, pDCs express increased levels of IFN-I 82 
mRNA and protein compared to healthy individuals (26, 27). PDCs sense HIV mainly through the 83 
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endosomal Toll-like receptor (TLR)7, although a role for TLR9 has not been excluded (4, 28). 84 
Blocking endosomal signaling decreased IFN-I levels and IA in treated immunological non-85 
responders (39). In acute SIV infections, pDCs are the main IFN-I-producing cells in lymph nodes 86 
(9, 16).  87 
HIV/SIV infections have an impact on pDC distribution, phenotype and function. It has been 88 
shown in SIVmac and SIVagm models that activated pDCs are rapidly recruited from the 89 
circulation to lymph nodes (7, 11, 20). Simultaneously, precursor pDCs rapidly egress from the 90 
bone marrow during acute SIVmac infection (7, 8). Precursor pDCs have a diminished capacity to 91 
produce IFN-I upon viral stimulation (8, 33). In line with this, human pDCs were found to 92 
produce less IFN-I upon HSV stimulation during late acute HIV infection, i.e. Fiebig stage III-IV 93 
(21, 32). This could also be explained by pDCs becoming refractory after HIV encounter (49). 94 
However, another study using purified pDCs reported an increased capacity to produce IFN-I 95 
upon AT2-inactivated HIV stimulation during post-acute HIV infection (Fiebig stage V-VI) (44). In 96 
vitro, HIV-1 is contained in an early endosomal compartment of pDCs, preventing pDC 97 
maturation and associating with a continued IFN-I producing capacity (31, 37). AGM peripheral 98 
blood mononuclear cells (PBMC) and lymph node cells collected during acute SIV infection 99 
mounted a stronger IFN-I response upon HSV stimulation than cells from uninfected animals 100 
(11). Thus, contradictory data exists on the IFN-I producing capacity of pDCs during acute 101 
HIV/SIV infections. The capacity of natural host pDCs to produce IFN-I in response to SIV during 102 
acute infection has not been investigated.  103 
In this study, we investigated the effect of SIV infection on AGM pDC function to identify events 104 
that could explain the different inflammatory profiles found in asymptomatic SIVagm infection 105 
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compared to pathogenic HIV/SIV infections. We assessed the IFN-I producing capacity of pDCs 106 
collected during SIVagm infection in response to in vitro stimulation with SIV and HSV. Our data 107 
suggest that precursor pDCs, with a decreased IFN-I producing capacity, circulate during acute 108 
SIVagm infection. We found that low BDCA-2 expression on pDCs could specifically block the 109 
sensing of SIV. Furthermore, we discovered that cells other than pDCs increase their capacity to 110 
sense virus during acute infection.  111 
Methods 112 
Ethics statement 113 
All animals were housed in the facilities of the Commissariat à l'Energie Atomique (CEA), 114 
Fontenay-aux-Roses, France, permit number: A 92-032-02) or of Institut Pasteur (Paris, France, 115 
permit number: A 78-100-3). All experimental procedures were conducted in strict accordance 116 
with the international European guidelines 2010/63/UE on protection of animals used for 117 
experimentation and other scientific purposes (French decree 2013-118). The CEA complies with 118 
Standards for Human Care and Use of Laboratory of the Office for Laboratory Animal Welfare 119 
(OLAW, USA) under OLAW Assurance number #A5826-01. All animal experimental protocols 120 
were approved by the Ethical Committee of Animal Experimentation (CETEA-DSV, IDF, France) 121 
(Notification numbers: 10-051b and 12-006).  122 
 123 
Animals and sample collection 124 
Twenty-four African green monkeys (Chlorocebus sabaeus) from Caribbean origin and ten 125 
Chinese rhesus macaques (Macaca mulatta) were used. Blood was collected by venipuncture on 126 
sodium heparin tubes that were shipped to Institut Pasteur. Fifteen AGMs were infected via 127 
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intravenous inoculation with 250 TCID50 of SIVagm.sab92018 and displayed high viremia levels, 128 
as described previously (10, 20). For eight AGMs, blood was drawn at days 2, 4, 7, 9, 11, 14, 25, 129 
31, 59, 85, 122, 183, 241 and 354 post infection (p.i.). Three more AGMs were sampled at days 130 
7, 14, 31 and 65 p.i. Another four AGMs were sampled at days 2, 4, 7, 9, 11, 14, 28, 43 and 58 131 
p.i. 132 
 133 
Stimulations 134 
PBMCs were isolated from whole blood after 1:1 dilution in PBS (Life Technologies), using 135 
Lymphocytes separation medium (Eurobio). Cells were spun down at 1100xg for 10’ in 50mL 136 
Leucosep tubes (Greiner Bio-one) and buffy coats were collected. Residual red blood cells were 137 
lysed for 6’ at room temperature in a sterile filtered buffer consisting of 1g/L potassium 138 
bicarbonate, 8.3 g/L ammonium chloride (both from Sigma) and 1 mM EDTA pH 8 (Life 139 
technologies). Cells were cultured at 0.5x10^6 cells/well in 24-wells plates (Costar) at 37˚ C, 5% 140 
CO2 and at 10^6 cells/mL in RPMI 1640 + glutamax medium (Life technologies) with 10% heat-141 
inactivated FCS (PAA or Eurobio) and penicillin-streptomycin (Life technologies). 142 
SIVagm.sab92018 or SIVmac251 was added at a concentration of 1500 ng/mL p27, HSV-1 was 143 
added at a 10^6 TCID50. A151, a gift from Pr. Olivier Schwartz (Institut Pasteur, Paris, France), and 144 
G-ODN were added to the cells simultaneously with the virus to block the TLR7 and TLR9 145 
pathway, respectively. Sodium azide was removed from antibodies against IFNαR2 (MMHAR-2, 146 
PBL) and BDCA-2 (AC144, Miltenyi) using PD Minitrap G-25 (GE Healthcare Life Sciences), 147 
followed by pre-incubation with these antibodies for an hour at 37˚ C before stimulation with 148 
virus. Previously frozen plasma on EDTA from five AGMs per timepoint was pooled for 149 
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incubations (four hour at 37˚ C) with PBMC. PBMC were mock-stimulated in medium for each of 150 
the experiments to assess spontaneous production of IFN-I. 151 
 152 
Functional Interferon alpha assay 153 
Bioactive Type I interferon was quantified as described earlier (1, 11). In short, Mardin-Darby 154 
Bovine Kidney (MDBK) cells were incubated with UV-inactivated supernatants for 18 hours, after 155 
which the cytopathic effect of vesicular stomatic virus was determined using the CellTiter 96® 156 
AQueous Non-Radioactive Cell Proliferation Assay (Promega). IC50  levels were calculated by 157 
normalization to a standard using R version 2.15.3 and the “drc” package (40, 41). 158 
 159 
Flow cytometry 160 
Antibodies used were: CD3 (SP34-2), HLA-DR (L243), CD123 (7G3), CD45 (D058-1283) (all BD 161 
Biosciences), CD20 (2H7, ebioscience), BDCA-2 (AC144) and IFN-α (LT27:295), (both Miltenyi). 162 
FcR Blocking Reagent (Miltenyi) was used to block unspecific antibody binding. For intracellular 163 
staining, cells were stimulated for two hours, after which brefeldin A was added and cells were 164 
incubated for another four hours at 37°C. Then, cells were labeled with surface-binding 165 
antibodies for ten minutes at room temperature. After fixation with 4% paraformaldehyde for 166 
six minutes at 37°C, cells were permeabilized using 10% saponin and incubated with IFNα 167 
antibody for fifteen minutes at room temperature. Events were collected on a LSR-II flow 168 
cytometer (BD), running FACS Diva 6.0 software (BD), and analyzed with FlowJo 9.4.10 169 
(TreeStar). Anti-mouse compensation beads (BD Biosciences) were used to define compensation 170 
levels. 171 
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 172 
Quantification of relative gene expression 173 
mRNA levels were quantified using RT-PCR as described previously on a 7500 real time PCR 174 
machine (Applied Biosystems) (25). Briefly, mRNA was reverse transcribed with the high 175 
capacity cDNA reverse transcription kit (Life technologies), followed by qPCR in triplicate with 176 
Taqman gene expression assays (Life technologies). The expression of each gene was 177 
normalized against that of 18S rRNA and relative expression levels were calculated using the 178 
∆∆ct method. 179 
 180 
Statistical analyses 181 
Statistical inference analyses were performed using Prism 5.0 (GraphPad). For paired testing of 182 
multiple groups without missing data, a Friedman test, followed by Dunn’s multiple comparison 183 
test, was employed. In case of missing data, the non-parametric Wilcoxon matched-pairs signed 184 
rank test (Wilcoxon) was used to test paired observations with no multiple-testing correction. 185 
The correlation between two continuous variables was assessed with the non-parametric 186 
Spearman test. 187 
 188 
Results  189 
SIVagm infection impacts the IFN-I producing capacity during the acute phase 190 
To determine the effect of SIV infection on AGM pDC function in vivo, we collected PBMC at 191 
different stages before and after infection and stimulated them with SIVagm in vitro. We 192 
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compared IFN-I production to stimulation with another virus, HSV. PBMC were collected at 193 
three timepoints before infection to get a stable baseline. To be able to get information on the 194 
earliest and later events after infection, cells were collected and stimulated at seven timepoints 195 
in acute infection and seven timepoints in chronic infection. Spontaneous IFN-I production by 196 
mock-stimulated PBMC was never observed, even during day two and nine p.i., when high IFN-I 197 
levels were present in the plasma. The AGM pDC response to in vitro SIV stimulation diminished 198 
during acute SIV infection starting at day four p.i. (Figure 1A). This diminished response 199 
persisted throughout acute infection until day thirty-one p.i. The median IFN-I level upon 200 
stimulation with SIVagm before infection was 78 IU/mL, which decreased to 10 IU/mL at the 201 
nadir, on days eleven, fourteen and twenty-five p.i. Statistically significant decreases were found 202 
at days four and nine p.i. (Wilcoxon, p = 0.03 and p = 0.02, respectively), compared to the pre-203 
infection values. As pDCs have been reported to be depleted from the blood in acute HIV-1, 204 
SIVmac and SIVagm infections (7, 38), we corrected for pDC counts (Figure 1B). Correction for 205 
pDC numbers did not change the observed decreased responsiveness to SIV during acute 206 
infection. The median of 0.057 IU/mL IFN-I per pDC before infection decreased to 0.022 IU/mL 207 
at day four p.i. (Wilcoxon, p = 0.04) and 0.014 IU/mL at day nine p.i. (Wilcoxon, p = 0.008). The 208 
decrease observed in the acute phase was temporary as the median IFN-I level in the chronic 209 
phase (after day twenty-five p.i.) returned close to pre-infection levels: 0.044 IU/mL per pDC.  210 
Upon in vitro stimulation with HSV of PBMC collected in acute SIVagm infection, we observed an 211 
increase in the levels of IFN-I produced compared to before infection (Figure 1C). At days two 212 
and nine p.i., there was a significant increase in IFN-I production, with levels of 1350 IU/mL 213 
(Wilcoxon, p = 0.02) and 1200 IU/mL IFN-I (Wilcoxon, p = 0.008) respectively, compared to the 214 
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median pre-infection level of 239 IU/mL IFN-I. The response to HSV-1 stimulation was not 215 
increased at any of the other days. When correcting for pDC numbers, we observed a more 216 
sustained increase in IFN-I producing capacity throughout acute and early chronic infection 217 
(Figure 1D). The levels of IFN-I produced upon HSV stimulation increased from 0.28 IU/mL per 218 
pDC before infection to a zenith of 1.11 IU/mL and 1.12 IU/mL on days nine and thirty-one p.i., 219 
respectively. This increase was statistically significant (Wicoxon, p < 0.05) at days seven, nine, 220 
fifty-nine and eighty-five. So, while the IFN-I response to SIV was decreased, the responsiveness 221 
to HSV was increased during acute SIVagm infection.  222 
Altered capacity to sense virus during acute SIVagm infection  223 
In order to understand the mechanisms underlying this differential response to SIV and HSV, we 224 
investigated the hypothesis that the SIV-sensing machinery of AGM pDCs is specifically altered 225 
by SIV infection, leading to a decreased capacity to respond to SIV, but not HSV.  HIV and HSV 226 
are mainly sensed by two distinct receptors in human pDCs, TLR7 and TLR9, respectively (4, 28). 227 
We investigated whether the sensing of SIV by AGM pDCs also occurs through endosomal TLRs, 228 
by stimulating PBMC of healthy AGMs with SIV in the presence of antagonists to TLR7 (A151) 229 
and/or to TLR9 (G-ODN) (Figure 2A). Blocking TLR7 and/or TLR9 decreased the response to SIV 230 
by AGM PBMC. IFN-I levels decreased from 60 IU/mL to 3 IU/mL and 10 IU/mL (Wilcoxon, p = 231 
0.002 and p = 0.004), after blocking TLR7 and TLR9, respectively. Given the stronger than 232 
expected inhibition upon TLR9 blockage, we repeated the experiment using MAC PBMC, which 233 
were stimulated with either SIVagm or SIVmac. For MAC PBMC, the response to both viruses 234 
(median of 147 IU/mL IFN-I) was lost upon blocking TLR7 (median of 14 IU/mL IFN-I), while it 235 
was not significantly inhibited upon blocking TLR9 (median of 89 IU/mL, Figure 2A). Since MAC 236 
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pDCs reacted the same to TLR9 inhibition irrespectively of the viral isolate used, it is unlikely 237 
that SIVagm is sensed more broadly than SIVmac. Therefore, AGM pDCs sense SIV through 238 
endosomal TLRs as reported for MAC and human before. 239 
BDCA-2 has been reported to be involved in attachment of HIV virions to the pDC surface (34). It 240 
has been shown the ratio of precursor pCD expressing low levels of BDCA-2 is increased during 241 
acute SIVmac infection (8, 33). If BDCA-2 is involved in the efficacy of endocytosis and sensing, 242 
lowered expression would specifically affect SIV but not HSV. We therefore evaluated the 243 
expression and function of BDCA-2 with respect to SIV- and HSV sensing. BDCA-2 levels on AGM 244 
pDC were lower during acute infection than before infection (mean fluorescent intensity (MFI) 245 
of 1486 pre-infection to a MFI of 660 at day 14 p.i., Wilcoxon, p < 0.01) (Figure 2B). This lower 246 
BDCA-2 MFI in the acute phase probably reflected the circulation of precursor pDCs, expressing 247 
low BDCA-2 levels, as BDCA-2 MFI closely correlated with the percentage of CD40+ pDCs 248 
(Spearman, r = 0.49, p = 0.0001) and HLA-DR expression on pDCs (Spearman, r = 0.75, p < 249 
0.0001) (Figure 2C). These molecules are expressed at lower levels on precursor pDC (33). To 250 
assess the role of BDCA-2 in SIV sensing by pDCs, we stimulated AGM PBMC with SIV and HSV in 251 
the presence of BDCA-2-blocking antibodies (Figure 2D). Blocking BDCA-2 prevented the 252 
response to SIVagm, but not to HSV, in a dose-dependent manner. An isotype control did not 253 
alter the IFN-I response to either SIV or HSV. At the end of the acute phase, BDCA-2 expression 254 
was similar to pre-infection levels, concomitant with the recovery of IFN-I production upon SIV 255 
stimulation in the chronic phase of SIVagm infection. Thus, the decreased response to SIV 256 
correlated with a decrease in BDCA-2 on pDCs and an increase in the frequency of precursor 257 
pDC in blood.  258 
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Non pDCs produce IFN-I upon HSV stimulation due to a positive IFN-I feedback loop in vivo 259 
A higher ratio of precursor pDC should impact both SIV and HSV responses. In order to further 260 
investigate the contrasting observations of an increased IFN-I response upon HSV stimulation 261 
and an increased circulation of precursor pDCs during acute SIVagm infection, PBMC collected 262 
during acute SIV infection were stimulated in vitro with HSV and analyzed by intracellular flow 263 
cytometric staining for pDC-associated IFNα production (Figure 2E). A median of 91% IFNα2+ 264 
pDCs upon stimulation with HSV was observed in healthy animals. During infection, the 265 
percentage of IFNα2+ pDCs in response to HSV stimulation fell to a nadir of 65% at day fourteen 266 
p.i. After the transition from the acute to the chronic phase of infection, AGM pDCs regained 267 
their capacity to produce IFN-I upon HSV stimulation. A non-parametric multiple comparison 268 
test showed this was significant (Friedman, p = 0.001). 269 
Although a decreased number of pDCs were producing IFN-I, a greater amount of IFN-I was 270 
detected in the supernatant of HSV-stimulated cells collected in acute infection (Figure 1C). To 271 
better understand this increased IFN-I production upon HSV stimulation, we searched for other 272 
cellular sources of IFN-I. After stimulation with HSV, up to three percent of CD123- cells, thus 273 
non-pDCs, were producing IFNα2 at days two, seven, eleven and fourteen p.i. (Figure 3A). The 274 
majority of these IFNα2+ cells were CD4- T cells, but other HLA-DR+ cells also produced IFNα2 275 
(Figure 4). In the absence of stimulation, no IFN-I production was observed at any time before 276 
and during infection (Figure 3B). 277 
This substantial non-pDC associated IFN-I production was surprising. A positive association 278 
between the levels of IFN-I in the plasma and the amount of IFN-I produced after stimulation 279 
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with HSV-1 existed during the acute phase (Spearman, r = 0.58, p < 0.001, Figure 5A and 5B). We 280 
therefore hypothesized that IFN-I induced a positive auto-feedback loop. To test this hypothesis, 281 
PBMC from healthy AGMs were incubated with plasma collected at various timepoints of 282 
SIVagm infection and then stimulated with HSV (Figure 5C). Pre-incubation with plasma 283 
collected during acute SIVagm infection increased the IFN-I response to HSV four-fold 284 
(Wilcoxon, p = 0.008) compared to pre-incubation with plasma from healthy animals. In contrast 285 
to acute phase plasma, plasma from animals in the chronic phase of infection did not increase 286 
the IFN-I response to HSV. To confirm that IFN-I mediated this increased response to HSV, we 287 
blocked the IFNα receptor 2 (IFNαR2) on AGM PBMC, incubated these cells with acute phase 288 
plasma and subsequently stimulated with HSV. Blocking with α-IFNαR2, but not with an isotype 289 
antibody, prevented the increase in IFN-I production (Wilcoxon, p = 0.008). Therefore, IFN-I was 290 
required for this increased response to HSV.  291 
As IFNαR signaling increased the response to HSV, we studied whether molecules involved in 292 
HSV sensing were increased during acute SIV infection. Expression levels of four known HSV 293 
sensors (TLR2, TLR3, TLR9 and IFI16) and three molecules associated with IFN-I production (IRF3, 294 
IRF5 and IRF7) were measured in PBMC during acute SIVagm infection. Expression levels of 295 
TLR3, TLR7, IFI16 and IRF7 were increased during acute SIVagm infection (Figure 6). In contrast 296 
expression levels of TLR2, TLR9, IRF3 and IRF5 were not increased, or even decreased, during 297 
acute SIVagm infection. TLR3 and IFI16 mRNA levels correlated with the amount of IFN-I 298 
produced upon HSV stimulation (Figure 5D, Spearman, r = 0.37, p = 0.01 and r = 0.39, p = 0.01, 299 
respectively). In contrast, IRF3, IRF5, IRF7, TLR2 and TLR9 expression levels did not associate 300 
with the IFN-I response upon HSV stimulation (Figure 5D and not shown). These data show that 301 
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SIV infection induces an upregulation of at least two sensors in PBMC via IFN-I, which could 302 
cause other cells than pDCs to increase their sensitivity for pathogen-associated molecular 303 
patterns and to produce IFN-I upon viral encounter.  304 
Discussion 305 
During acute SIV infection, AGM PBMC produced less IFN-I upon in vitro stimulation with SIV, 306 
but more upon stimulation with HSV, compared to before infection. Blocking BDCA-2 reduced 307 
the in vitro IFN-I response to SIV, but not to HSV. During acute infection, we observed a lower 308 
BDCA-2 expression on pDCs, which could thus specifically impact SIV sensing. Moreover, our 309 
data suggest an egress of precursor pDCs during acute SIVagm infection, similar to what has 310 
been reported for SIVmac infection (7, 8). As precursor pDC are less efficient in producing IFN-I 311 
(33), this could also explain the decreased response to SIV.  312 
While the IFN-I production increased upon stimulation of PBMC with HSV during the acute 313 
phase, the percentage of pDCs that was producing IFN-I in response to HSV decreased. 314 
Surprisingly, cells other than pDCs, notably T cells and also HLA-DR+CD3- cells, started producing 315 
IFN-I upon in vitro stimulation with HSV during acute SIVagm infection. These data are in 316 
agreement with immunohistochemistry data from the spleen of late-stage HIV-infected patients 317 
where IFNα colocalized only with few pDCs, but rather with other cells, including T and B 318 
lymphocytes, mDCs, and macrophages (36). It is possible that in immunocompromised patients, 319 
reactivated latent viruses, such as cytomegalovirus, a member of the herpesviridae family, were 320 
triggering this non-pDC associated IFNα-production, as these are abundant during late-stage HIV 321 
infection (14). Moreover, the expanded gut virome and microbial translocation observed in 322 
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SIVmac, but not SIVagm, infection could contribute to chronic IA by triggering IFN-I responses in 323 
cells normally not associated with these responses (15, 24). 324 
The increased sensing of HSV by non-pDCs was due to a positive auto-feedback loop of IFN-I, 325 
which is transiently present at high levels in the plasma during the acute phase of HIV/SIV 326 
infections and also in late stage patients. While our data do not exclude that other factors might 327 
be required in addition to IFN-I for this enhanced viral sensing, it is unlikely that SIV particles in 328 
the plasma induced the increased IFN-I response as plasma from chronically infected animals 329 
did not increase responsiveness. The increased response to HSV was associated with increased 330 
expression levels of the viral sensors TLR3 and IFI16. These data are in line with a study showing 331 
that TLR3-mediated sensing dominates the IFN-I response during in vivo HSV infection in mice 332 
after the initial pDC-associated IFN-I responses (48). Such increased sensitivity might also occur 333 
in HIV and SIVmac infections, which could have gone unnoticed as most studies using viral 334 
stimuli other than SIV did not analyze such early and numerous timepoints as done here (11, 21, 335 
32). 336 
Collectively, our data show that SIVagm infection strongly impacts AGM pDC function and 337 
dynamics during acute SIV infection, similar to what happens in HIV and SIVmac infections in 338 
blood (7, 8). These modifications normalize however after acute SIVagm infection. The 339 
previously reported low level of ISG expression during the chronic phase of SIVagm infection is 340 
therefore, as suggested earlier, not a reflection of lack of IFN-I producing capacity by AGM pDCs 341 
(5, 19). Furthermore, these results suggest that cells that are not classically involved in IFN-I 342 
associated inflammation might be contributing to this during chronic HIV infection due to 343 
upregulation of viral sensors in response to the existing inflammatory environment. These data 344 
17 
 
suggest that specifically targeting pDC-driven IFN-I responses is not sufficient to reduce 345 
inflammation and that cells other than pDCs could be crucial in maintaining persistent 346 
inflammation in HIV infection. 347 
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 Figure legends 570 
 571 
Figure 1. Dynamics of type I interferon producing capacity during SIVagm infection. We 572 
stimulated AGM PBMC collected before and during the course of SIVagm infection and 573 
measured IFN-I production. The x-axis displays the day post infection at which cells were 574 
isolated and stimulated with (A, B) SIV or (C, D) HSV. The y-axis shows (A, C) the total IFN-I 575 
produced after 18 hours of stimulation or (B,D) the same IFN-I production corrected for the 576 
number of plasmacytoid dendritic cells among the PBMC. Grey circles represent pre-infection, 577 
upward triangles acute infection and downward triangles post-acute and chronic infection 578 
timepoints. The dotted line shows the median for all pre-infection timepoint stimulations. 579 
Symbols represent individual animals (n = 5-11 for each time point). * Wilcoxon, p < 0.05, ** 580 
Wilcoxon, p < 0.01. The p-values indicate a significant difference compared to the pre-infection 581 
baseline. 582 
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Figure 2. Molecules involved in SIV sensing by AGM plasmacytoid dendritic cells. (A) PBMC 583 
from ten non-infected AGMs (open circles) and seven to nine MACs (closed circles) were 584 
stimulated with mock (grey) or SIVagm or SIVmac (black). A151 [5μg/mL] and G-ODN [0.5 μM] 585 
were added at the same time as SIV to inhibit the TLR7 and TLR9 pathway respectively. (B) 586 
Longitudinal follow-up of MFI levels of BDCA-2 on pDCs during early SIVagm infection. BDCA-2 587 
expression was followed for four AGMs. (C) Expression of BDCA-2, CD40 and HLA-DR was 588 
measured simultaneously on AGM pDCs. pDCs were defined as CD20-HLA-DR+CD123+ BDCA2+ 589 
cells. MFI = mean fluorescent intensity, r = Spearman’s correlation. (D)  α-BDCA2 or irrelevant 590 
IgG1 antibodies were added to PBMC of six uninfected AGM for 1 hour at concentrations of 1 591 
μg/mL and 10 μg/mL. After stimulation with SIVagm (S, light grey) or HSV-1 (H, dark grey) for 18 592 
hours, we measured IFN-I levels in the supernatant. IFN-I levels were normalized to IFN-I 593 
produced after no incubation with antibodies. The dotted line represents no difference 594 
compared to stimulation without antibodies. (E) Percentage of IFNα2+ pDCs upon in vitro HSV 595 
stimulation at different timepoints of SIVagm infection. PBMC were collected before and after 596 
SIVagm infection and pDCs analyzed for IFNα2 production after in vitro stimulation. pDCs were 597 
defined as CD3-HLA-DR+CD123+ cells. Symbols represent individual animals. * Wilcoxon, p < 598 
0.05, ** Wilcoxon, p < 0.01, *** Wilcoxon, p < 0.001 599 
Figure 3. Non pDC-associated IFNα production. Dot plots showing CD123 and IFNα2 expression 600 
on whole PBMC collected throughout SIVagm infection. One representative AGM (SV048) out of 601 
four analyzed is shown. (A) Cells after stimulation with HSV. (B) Mock-stimulated cells. 602 
Figure 4. Identification of cell types producing IFN-I upon HSV stimulation. PBMC from one 603 
representative AGM (SV061) out of four are shown. The chosen timepoint day two post 604 
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infection is representative of days two, nine and eleven post infection. PBMC were gated for 605 
distinct cell populations to identify cell types that produce IFNα2. 5.5% of the CD4- T cells, 85.7% 606 
of the pDCs and 1% of non-T, non-pDC cells were IFNα+ after HSV stimulation. All IFNα-607 
producing cells expressed high levels of HLA-DR. 608 
Figure 5. Auto-feedback loop of IFN-I during acute SIV infection of AGMs. (A) IFN-I levels 609 
present in the plasma of eight acutely SIV infected AGMs. (B) Correlation between IFN-I levels in 610 
the plasma of AGMs during acute SIVagm infection in vivo and the amount of IFN-I produced 611 
upon in vitro HSV stimulation. (C) Plasma collected from healthy AGMs, acutely infected AGMs 612 
and chronically infected AGMs was diluted to 5% in RPMI and added to PBMC of eight healthy 613 
AGMs. After four hours of incubation, cells were stimulated with herpes simplex virus 1 (HSV) 614 
and after another eighteen hours, supernatants were collected for IFN-I quantification. PBMC 615 
were incubated with anti-IFNα Receptor 2 (α-IFNaR2) or with an irrelevant antibody as a 616 
negative control at 10 μg/mL for one hour to block IFNα signaling before adding plasma. 617 
Symbols represent individual animals. (D) Correlation between mRNA levels of known HSV 618 
sensors in PBMC of AGMs during acute SIVagm infection in vivo and the amount of IFN-I 619 
produced upon in vitro HSV stimulation of the same PBMC. ** Wilcoxon, p < 0.01. IFI16 = 620 
Interferon, Gamma-Inducible Protein 16. TLR = Toll-like receptor. r = Spearman’s correlation. 621 
Figure 6. Gene expression profiles of genes involved in HSV sensing and IFN-I responses. 622 
mRNA levels were measured in PBMC from six animals (same animals as in Figure 5) during 623 
SIVagm infection. The grey lines indicate individual animals and the black line the median of all 624 
animals * Wilcoxon, p < 0.05, ** Wilcoxon, p < 0.01, *** Wilcoxon, p < 0.001. The p-values 625 
indicate a significant difference compared to the pre-infection baseline. 626 






